Clinical Trial Update: Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing whether combining propranolol with pembrolizumab can re-sensitize checkpoint inhibitor-refractory metastatic or unresectable tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Propranolol (propranolol)

Snippet

Sponsor: Emory University | Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Status: NOT_YET_RECRUITING